Malignant Glioma — Trials

Malignant Glioma — Trials · CancerIndex

Clinical trials

Registered studies

2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 589
Recruiting: 314
Ph III recruiting: 16
Growth YoY: +38.9%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (325)

clinicaltrialsPublishedShowing 251–253 of 253 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05540275	Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	not yet recruiting	Phase 2	30	Henan Provincial People's HospitalOTHER	1	Oct 6, 2023	clinicaltrials
NCT05842746	Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma	not yet recruiting	Phase 2	74	Peking Union Medical College HospitalOTHER	1	May 6, 2023